vitreomacular adhesion vma human medical condition vitreous gel simply vitreous aka vitreous humour human eye adheres retina abnormally strong manner eye ages common vitreous separate retina separation complete ie still adhesion create pulling forces retina may result subsequent loss distortion vision adhesion dangerous resulting pathological vitreomacular traction vmt cause severe ocular damage current standard care treating adhesions pars plana vitrectomy ppv involves surgically removing vitreous eye biological agent noninvasive treatment adhesions called ocriplasmin approved fda october traction caused vma underlying pathology eye disease called symptomatic vma evidence symptomatic vma contribute development several wellknown eye disorders macular hole macular pucker cause visual impairment including blindness may also associated agerelated macular degeneration amd diabetic macular edema dme retinal vein occlusion diabetic retinopathy drcitation needed time common vitreous within human eye liquify collapse processes known syneresis synchisis respectively creates fluidfilled areas combine form pockets vitreous gel mostly liquid small concentrations collagen liquid pockets close enough interface vitreous gel retina cause complete separation vitreous retina normally occurring process older humans called posterior vitreous detachment pvd pvd dangerous natural processcitation needed separation vitreous retina complete areas focal attachment adhesions occur ie vma pulling forces traction adhesion retinal surface sometimes cause edema within retina damage retinal blood vessels causing bleeding damage optic nerve causing disruption nerve signals sent brain visual processing important note vma dangerous resultant pulling retina called vitreomacular traction vmt causes damage size strength vma determine variety resulting pathologies vma also lead development vmttractionrelated complications macular puckers macular holes leading distorted vision metamorphopsia epiretinal membrane tractional macular oedema myopic macular retinoschisis visual impairment blindness incidence vma reported high patients macular hole patients vitreomacular traction syndrome idiopathic epimacular careful eye examination ophthalmologist optometrist critical diagnosing symptomatic vma imaging technologies optical coherence tomography oct significantly improved accuracy diagnosing symptomatic vmacitation needed new fda approved drug released market late jetrea brand name ocriplasmin generic name first drug kind used treat vitreomacular adhesioncitation needed mechanism action ocriplasmin truncated human plasmin proteolytic activity protein components vitreous body vitreoretinal interface dissolves protein matrix responsible vitreomacular adhesion adverse drug reactions decreased vision potential lens subluxation dyschromatopsia yellow vision eye pain floaters blurred vision new drug comparison rating gave jetea indicating important advance previously recommended treatment available patient mild symptomatic vma symptomatic vma patients significant vision loss standard care pars plana vitrectomy ppv involves surgically removing vitreous eye thereby surgically releasing symptomatic vma words vitrectomy induces pvd release tractionadhesion retina estimated vitrectomy procedures performed globally annual basis united states alone standard ppv procedure lead serious including smallgauge complications include retinal detachment retinal tears endophthalmitis postoperative cataract formation additionally ppv may result incomplete separation may potentially leave nidus vasoactive vasoproliferative substances may induce development fibrovascular membranes invasive surgical procedure ppv introduces trauma vitreous surrounding data showing nonsurgical induction pvd using ocriplasmin recombinant protease activity fibronectin offer benefits successful pvd eliminating risks associated surgical procedure ie vitrectomy pharmacologic vitreolysis improvement invasive surgery induces complete separation creates physiologic state vitreomacular interface prevents development fibrovascular membranes less traumatic vitreous potentially thrombogenics still developing ocriplasmin biological agent ocriplasmin approved recently name jetrea use united states experimental test injections perfluoropropane symptomatic eyes patients showed vitreomacular traction resolved eyes within month resolved eyes within systematic review found highcertainty evidence ocriplasmin compared treatment increases chance resolution improves vision people symptomatic vma ocriplasmin probably reduces need surgery adverse events eyes treated ocriplasmin compared control httpsenwikipediaorgwikivitreomacularadhesion